Cadence Biomedical

Cadence Biomedical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

Cadence Biomedical is a private medical device company focused on neurorehabilitation through its flagship product, Kickstart. This wearable device provides powered assistance to stabilize the hip and leg, guiding users through a proper step pattern to re-learn walking. The device is covered by Medicare and private insurance, targeting both individual patients for home use and rehabilitation clinics for therapeutic applications. The company appears to be in a commercial, revenue-generating stage, leveraging clinical evidence and user testimonials to drive adoption.

NeurorehabilitationStrokeSpinal Cord InjuryMultiple Sclerosis

Technology Platform

Wearable exotendon device providing mechanical, reflexive step assistance to stabilize the hip and leg and promote re-learning of natural gait patterns without electrical stimulation.

Funding History

3
Total raised:$7.5M
Grant$1M
Series A$5M
Seed$1.5M

Opportunities

Large and growing neurorehabilitation market driven by aging demographics and improved trauma survival.
Dual revenue model targeting both clinical therapy settings and direct-to-patient home use, facilitated by Medicare coverage.
Potential to establish a new standard of care in gait training with strong clinical evidence.

Risk Factors

Heavy dependence on stable and broad insurance reimbursement, particularly from Medicare.
Competition from other rehabilitation technologies and conventional therapy methods.
Execution risk in scaling commercial operations and driving adoption in a conservative healthcare segment.

Competitive Landscape

Kickstart competes in the assistive and rehabilitative device market, facing competition from robotic exoskeletons (e.g., Ekso Bionics, ReWalk), functional electrical stimulation systems (e.g., Bioness), and traditional gait training equipment. Its differentiation lies in its unique exotendon mechanism, lightweight design, and focus on promoting reflexive, patient-initiated movement rather than fully pre-programmed assistance.